Single-drug chemotherapy was employed in a multicentric co-operative trial. Adriamycin was given to 18 patients, VM-26 to 30 and Bleomycin to 33. Almost all patients were suffering from a T3 or T4 bladder cancer with known métastasés in almost 40% of cases. The vast majority of patients had already received previous treatment either chemotherapy, surgery or irradiation. Complete regression was obtained in 5 % of cases; partial objective regression in 11.1 % of patients treated with Adriamycin, 26.6 % with VM-26 and 33.3 % with Bleomycin. The results were uniformly better when high dosages of drug were employed. No clear-cut superiority of one drug over the others can be demonstrated.